OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 151 filers reported holding OCULAR THERAPEUTIX INC in Q4 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,247 | -39.1% | 397 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $2,049 | -2.1% | 397 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $2,092 | +87.5% | 397 | 0.0% | 0.00% | +100.0% |
| Q4 2022 | $1,116 | -44.2% | 397 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $2,000 | 0.0% | 397 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $2,000 | 0.0% | 397 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $2,000 | -33.3% | 397 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $3,000 | -25.0% | 397 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $4,000 | -33.3% | 397 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $6,000 | -14.3% | 397 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $7,000 | -12.5% | 397 | 0.0% | 0.01% | -14.3% |
| Q4 2020 | $8,000 | -55.6% | 397 | -83.4% | 0.01% | -56.2% |
| Q3 2020 | $18,000 | -10.0% | 2,397 | 0.0% | 0.02% | -27.3% |
| Q2 2020 | $20,000 | +81.8% | 2,397 | 0.0% | 0.02% | +69.2% |
| Q1 2020 | $11,000 | +22.2% | 2,397 | 0.0% | 0.01% | +30.0% |
| Q4 2019 | $9,000 | – | 2,397 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 3,804,788 | $15,105,000 | 43.34% |
| Versant Venture Management, LLC | 2,215,384 | $8,795,074,000 | 2.90% |
| Opaleye Management Inc. | 1,900,000 | $7,543,000 | 2.09% |
| SV Health Investors, LLC | 628,236 | $2,494,000 | 1.46% |
| Endurant Capital Management LP | 716,124 | $2,843,000 | 1.12% |
| DELTEC ASSET MANAGEMENT LLC | 824,747 | $3,274,000 | 0.72% |
| NOTTINGHAM ADVISORS, INC. | 146,946 | $583,000 | 0.08% |
| Jump Trading, LLC | 39,255 | $156,000 | 0.05% |
| Man Group plc | 1,723,456 | $6,842,000 | 0.03% |
| JGP Global Gestao de Recursos Ltda. | 13,880 | $55,000 | 0.02% |